Purine Antagonists for Chronic Lymphocytic Leukaemia

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 4, 2006, Pages

  Steurer, Michael ^a   Pall, Georg ^a   Richards, Sue ^b   Schwarzer, Guido ^c   Bohlius, Julia ^d   Greil, Richard ^e  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

^e PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CLADRIBINE; DRUG DERIVATIVE; FLUDARABINE; PENTOSTATIN; VIDARABINE;

B CELL LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTINEOPLASTIC AGENTS; CHLORAMBUCIL; CLADRIBINE; HUMANS; LEUKEMIA, B-CELL, CHRONIC; PENTOSTATIN; RANDOMIZED CONTROLLED TRIALS; VIDARABINE;

EID: 33750108935     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004270.pub2     Document Type: Review

References (39)

1. The French Cooperative Group on CLL, Johnson S, Smith AG, Löffler H, Osby E, Juliusson G, Emmerich B, Wyld PJ, Hiddemann W. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996;347(9013):1432-38. [MEDLINE: 8676625]
2. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, Rapp MJ, Jaubert J, Autrand C, Divine M, Dreyfus B, Maloum K, Travade P, Dighiero G, Binet JL, Chastang C. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98(8):2319-25. [MEDLINE: 11588025]
3. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. New England Journal of Medicine 2000;343(24):1750-57. [MEDLINE: 11114313]
4. Robak T, Blonski JZ, Kasznicki M, Blasinska-Morawiec M, Krykowski E, Dmoszynska A, Mrugala-Spiewak H, Skotnicki AB, Nowak W, Konopka L, Ceglarek B, Maj S, Dwilewicz-Trojaczek J, Hellmann A, Urasinski I, Zdziarska B, Kotlarek-Haus S, Potoczek S, Grieb P. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96(8):2723-2729. [MEDLINE: 11023504]
5. Spriano M, Chiurazzi F, Liso V, Mazza P, Molica S, Gobbi M. Multicentre prospective randomized trial of fludarabine versus chlorambucil and prednisone in previously untreated patients with active B-CLL. Hematology and Cell Therapy. 2000; Vol. 42, issue 1:93. [MEDLINE: 11036943]
6. Jaksic B, Brugiatelli M, Suciu S, Beaumelou E, Wijermans PW, Delmer A, Roozendaal KJ, Teixeira A, Jehn U, Feremans W, Belhabri A, Egyed M, Venditi A, Indrak K, Cevreska L, Rodts P, Solbu G, Willemze R, De Witte TM, and for EORTC Leukemia Group. Fludarabine vs high-dose chlorambucil in advanced B-cell chronic lymphocytic leukemia (B-CLL): Results of EORTC phase-II randomized trial after 4 years of median follow-up. Blood. 2000; Vol. 96:758a. [MEDLINE: 11109927]
7. CLL5, German CLL Study Group. Ongoing study 08/1999.
8. International Phase III trial on B-CLL. Ongoing study 11/1997.
9. MRC CLL4 trial. Ongoing study 03/1999.
10. Anaissie EJ, Kontoyiannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998;129(7):559-566. [MEDLINE: 9758577]
11. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48(1):198-206. [MEDLINE: 7237385]
12. Carli PM, Coebergh JW, Verdecchia A. Variation in survival of adult patients with haematological malignancies in Europe since 1978. EUROCARE Working Group. Eur J Cancer 1998;34(14):2253-2263. [MEDLINE: 10773535]
13. Cartwright RA, Alexander FE, McKinney PA, Rickets TJ. Leukemia and Lymphoma: An atlas of distribution within areas of England and Wales 1984-88. Leukaemia Research Fund. London: Leukemia Research Fund, 1990.
14. Chin Yee I, Makarski J, Browman G, Wong S, Esmail R, Meyer R and The Hematology Disease Site Group (Cancer Care Ontario). Fludarabine in intermediate- and high-risk chronic lymphocytic leukemia. www.ccopebc.ca/guidelines/hem/cpg6_1f.html 2002.
15. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. American Journal of Hematology 1988;29(3):152-163. [MEDLINE: 3189311]
16. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87(12):4990-7. [MEDLINE: 8652811]
17. CLL Trialists´ Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta- analysis of the randomized trials. CLL Trialists' Collaborative Group. Journal of the National Cancer Institute 19-5-1999;91(10):861-868. [MEDLINE: 10340906]
18. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marce S, Lopez-Guillermo A, Campo E, Montserrat E. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348(18):1764-1775. [MEDLINE: 12724482]
19. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94(6):1840-1847. [MEDLINE: 10477721]
20. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343(26):1910-1916. [MEDLINE: 11136261]
21. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. British Medical Journal 1997;315(7121):1533-37. [MEDLINE: 9432252]
22. The French Cooperative Group on Chronic Lymphocytic Leukemia. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood 1990;75(7):1422-25. [MEDLINE: 2180493]
23. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, Oscier DG. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99(3):1023-1029. [MEDLINE: 11807008]
24. Ihaka R, Gentleman R. R: A Language for Data Analysis and Graphics. Journal of Computational and Graphical Statistics 1996;5(3):299-314. [http://search.epnet.com/direct.asp?an=9609114569&db=bsh]
25. Jaksic B, Brugiatelli M, Krc I, Losonczi H, Holowiecki J, Planinc-Peraica A, Kusec R, Morabito F, Iacopino P, Lutz D. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer 1997;79(11):2107-2114. [MEDLINE: 9179056]
26. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989;74(1):19-25. [MEDLINE: 2473795]
27. Kimby E, Brandt L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia. Acta Oncologica 2001;40(2-3):224-230. [MEDLINE: 11441934]
28. Kipps TJ. Chronic lymphocytic leukemia and related diseases. William´s Hematology. McGraw-Hill Education (ISE Editions), 1995:1017.
29. Levy V, Porcher R, Delabarre F, Leporrier M, Cazin B, Chevret S. Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis. J Clin Epidemiol 2001;54(7):747-754. [MEDLINE: 11438417]
30. Molica S, Levato D. What is changing in the natural history of chronic lymphocytic leukemia?. Haematologica 2001;86(1):8-12. [MEDLINE: 11146563]
31. Nabhan C, Gartenhaus RB, Tallman MS. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res 2004;28(5):429-442. [MEDLINE: 15068894]
32. Panasci L, Paiement JP, Christodoulopoulos G, Belenkov A, Malapetsa A, Aloyz R. Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin Cancer Res 2001;7(3):454-461. [MEDLINE: 11297233]
33. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34. [MEDLINE: 9921604]
34. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46(2):219-34. [MEDLINE: 1139039]
35. Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia 2002;16(6):1015-1027. [MEDLINE: 12040433]
36. Rozman C, Montserrat E. Chronic lymphocytic leukemia. New England Journal of Medicine 1995;333(16):1052-57. [MEDLINE: 7675049]
37. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Programm. National Cancer Institute, 2004.
38. Summerfield GP, Taylor PR, Mounter PJ, Proctor SJ. High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma. Br J Haematol 2002;116(4):781-786. [MEDLINE: 11886381]
39. Tondini C, Balzarotti M, Rampinelli I, Valagussa P, Luoni M, De Paoli A, Santoro A, Bonadonna G. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. Ann Oncol 2000;11(2):231-233. [MEDLINE: 10761763]